Investigation of Chitosan-g-PEG Grafted Nanoparticles As a Half-life Enhancer Carrier for Tissue Plasminogen Activator Delivery

Overview

Journal IET Nanobiotechnol

Publisher Wiley

Specialty Biotechnology

Date 2021 Jan 5

PMID 33399124

Authors

Arezoo Khosravi

Hadi Baharifar

Mohamad Hasan Darvishi

Ali Akbar Karimi Zarchi

Affiliations

Soon will be listed here.

Abstract

Tissue plasminogen activator (tPA) a thrombolytic agent is commonly used for digesting the blood clot. tPA half-life is low (4-6 min) and its administration needs a prolonged continuous infusion. Improving tPA half-life could reduce enzyme dosage and enhance patient compliance. Nano-carries could be used as delivery systems for the protection of enzymes physically, enhancing half-life and increasing the stability of them. In this study, chitosan (CS) and polyethylene glycol (PEG) were used for the preparation of CS-g-PEG/tPA nanoparticles (NPs) via the ion gelation method. Particles' size and loading capacity were optimised by central composite design. Then, NPs cytotoxicity, release profile, enzyme activity and in vivo half-life and coagulation time were investigated. The results showed that NPs does not have significant cytotoxicity. Release study revealed that a burst effect happened in the first 5 min and resulted in releasing 30% of tPA. Loading tPA in NPs could decrease 25% of its activity but the half-life of it increases in comparison to free tPA in vivo. Also, blood coagulation time has significantly affected (-value = 0.041) by encapsulated tPA in comparison to free tPA. So, CS-g-PEG/tPA could increase enzyme half-life during the time and could be used as a non-toxic candidate delivery system for tPA.

References

Wang H, Jia Y, Hu W, Jiang H, Zhang J, Zhang L . Effect of preparation conditions on the size and encapsulation properties of mPEG-PLGA nanoparticles simultaneously loaded with vincristine sulfate and curcumin. Pharm Dev Technol. 2012; 18(3):694-700. DOI: 10.3109/10837450.2012.696267. View

Yuan Y, Chesnutt B, Haggard W, Bumgardner J . Deacetylation of Chitosan: Material Characterization and in vitro Evaluation via Albumin Adsorption and Pre-Osteoblastic Cell Cultures. Materials (Basel). 2017; 4(8):1399-1416. PMC: 5448679. DOI: 10.3390/ma4081399. View

Chung T, Wang S, Tsai W . Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles. Biomaterials. 2007; 29(2):228-37. DOI: 10.1016/j.biomaterials.2007.09.027. View

Gnach A, Lipinski T, Bednarkiewicz A, Rybka J, Capobianco J . Upconverting nanoparticles: assessing the toxicity. Chem Soc Rev. 2014; 44(6):1561-84. DOI: 10.1039/c4cs00177j. View

Rodrigues S, Rosa da Costa A, Grenha A . Chitosan/carrageenan nanoparticles: effect of cross-linking with tripolyphosphate and charge ratios. Carbohydr Polym. 2014; 89(1):282-9. DOI: 10.1016/j.carbpol.2012.03.010. View

Thomas S, Madaan T, Iqbal Z, Talegaonkar S . Box-Behnken Design of Experiment Assisted Development and Optimization of Bendamustine HCl loaded Hydroxyapatite Nanoparticles. Curr Drug Deliv. 2018; 15(9):1230-1244. DOI: 10.2174/1567201815666180620123347. View

Huang X, Moreton F, Kalladka D, Cheripelli B, MacISaac R, Tait R . Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke. Stroke. 2015; 46(12):3543-6. DOI: 10.1161/STROKEAHA.115.011290. View

Rajagopalan S, Gonias S, Pizzo S . A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function. J Clin Invest. 1985; 75(2):413-9. PMC: 423508. DOI: 10.1172/JCI111715. View

Sung Y, Kim S . Recent advances in polymeric drug delivery systems. Biomater Res. 2020; 24:12. PMC: 7285724. DOI: 10.1186/s40824-020-00190-7. View

10.

Camiolo S, Thorsen S, ASTRUP T . Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proc Soc Exp Biol Med. 1971; 138(1):277-80. DOI: 10.3181/00379727-138-35878. View

11.

Disharoon D, Marr D, Neeves K . Engineered microparticles and nanoparticles for fibrinolysis. J Thromb Haemost. 2019; 17(12):2004-2015. PMC: 6893081. DOI: 10.1111/jth.14637. View

12.

Heid S, Unterweger H, Tietze R, Friedrich R, Weigel B, Cicha I . Synthesis and Characterization of Tissue Plasminogen Activator-Functionalized Superparamagnetic Iron Oxide Nanoparticles for Targeted Fibrin Clot Dissolution. Int J Mol Sci. 2017; 18(9). PMC: 5618486. DOI: 10.3390/ijms18091837. View

13.

Abdel-Hafez S, Hathout R, Sammour O . Towards better modeling of chitosan nanoparticles production: screening different factors and comparing two experimental designs. Int J Biol Macromol. 2013; 64:334-40. DOI: 10.1016/j.ijbiomac.2013.11.041. View

14.

Yang H, Hua M, Lin K, Wey S, Tsai R, Wu S . Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis. Int J Nanomedicine. 2012; 7:5159-73. PMC: 3464084. DOI: 10.2147/IJN.S32939. View

15.

Liang H, Jiang S, Yuan Q, Li G, Wang F, Zhang Z . Co-immobilization of multiple enzymes by metal coordinated nucleotide hydrogel nanofibers: improved stability and an enzyme cascade for glucose detection. Nanoscale. 2016; 8(11):6071-8. DOI: 10.1039/c5nr08734a. View

16.

Atacan K, Cakiroglu B, Ozacar M . Improvement of the stability and activity of immobilized trypsin on modified Fe3O4 magnetic nanoparticles for hydrolysis of bovine serum albumin and its application in the bovine milk. Food Chem. 2016; 212:460-8. DOI: 10.1016/j.foodchem.2016.06.011. View

17.

Pourmortazavi S, Taghdiri M, Makari V, Rahimi-Nasrabadi M . Procedure optimization for green synthesis of silver nanoparticles by aqueous extract of Eucalyptus oleosa. Spectrochim Acta A Mol Biomol Spectrosc. 2014; 136 Pt C:1249-54. DOI: 10.1016/j.saa.2014.10.010. View

18.

Baharifar H, Amani A . Size, Loading Efficiency, and Cytotoxicity of Albumin-Loaded Chitosan Nanoparticles: An Artificial Neural Networks Study. J Pharm Sci. 2016; 106(1):411-417. DOI: 10.1016/j.xphs.2016.10.013. View

19.

Amidi M, Mastrobattista E, Jiskoot W, Hennink W . Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev. 2009; 62(1):59-82. DOI: 10.1016/j.addr.2009.11.009. View

20.

Burrows N, Harvey S, Idesis F, Murphy C . Understanding the Seed-Mediated Growth of Gold Nanorods through a Fractional Factorial Design of Experiments. Langmuir. 2016; 33(8):1891-1907. DOI: 10.1021/acs.langmuir.6b03606. View